antibodies

A clinical trial run by the NIH exploring the efficacy of convalescent plasma in treating mild to moderate COVID-19 patients has been halted. In a similar conclusion to prior trials, the once-promising treatment was deemed unlikely to be of any benefit.

Promising interim data testing the efficacy of a monoclonal antibody cocktail developed to prevent SARS-CoV-2 infection has been announced, but there are concerns the prohibitive cost of producing the therapy will limit widespread use.

Eli Lilly has announced its antibody treatment can reduce a person’s risk of contracting COVID-19 by up to 80 percent. These preliminary results suggest the treatment may be an effective way to rapidly suppress outbreaks in unvaccinated communities.

Early findings from a clinical trial suggest severely ill COVID-19 patients do not benefit from a therapy involving infusions of plasma from those recovered from the disease. The trial continues to investigate the therapy in moderately ill patients.

New research has shown how immune cells produced in the gut play a protective role during MS flare-ups. For the first time scientists have shown how these immune cells travel up to the brain and potentially help shift a disease flare-up into remission.

The FDA has just approved the first coronavirus-specific antibody treatment for moderate cases of COVID-19. The focused Emergency Use Authorization (EUA) is aimed at newly diagnosed infections at the highest risk of progressing to severe disease.

A new study, published in the journal Nature, is describing the surprising discovery of a previously unknown gut-brain link. The research reveals certain immune cells that inhabit a protective membrane surrounding the brain actually originate in the gut.

Researchers are suggesting antibodies produced by the immune system response to SARS-CoV-2 decline in the months following initial infection. Testing hundreds of thousands of subjects over three months, the study raises questions over long-term immunity.

In a recent video message Donald Trump attributed his rapid COVID-19 recovery to a new experimental therapy he called ‘Regeneron’ and subsequently referred to it as a “cure”. What do we know about this new experimental drug? Is it safe? And what does it actually do?

Novel research has described the discovery of opioid antibodies produced by the immune system following chronic opioid use. The researchers suggest these antibodies may be responsible for some negative side effects seen in long-term opioid users.

Scientists have designed a novel antibody that can accurately detect the toxic protein oligomers suspected to cause the degeneration associated with Alzheimer’s disease. The breakthrough hopes to lead to improved drug design and clinical testing.

As researchers rekindle a more than 100-year-old therapy, using blood from recovered COVID-19 subjects as a treatment for newly infected patients, a team in New York is thrusting this old, experimental treatment into the 21st century.